Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China

Korábbi kezelés

• Previous diagnosis of CML-accelerated phase or blast crisis;
• Concurrent other malignancies (refer to the International ICD-11 diagnosis codes, with diagnostic text including carcinoma, malignant neoplasm, etc.);

Más betegség

• Other conditions that are considered not suitable for the study by the investigator.

Egyéb

• Patients meeting any of the following criteria are not eligible for inclusion in this study:
• Currently participating in an interventional clinical study for CML;
• Having rare, atypical transcript types that cannot be standardised internationally;
• Women who are pregnant, lactating or planning to become pregnant during the study;

• Patients eligible for inclusion in this study must meet all the following criteria:
• 18 years or older at the time of ICF signing;
• Newly diagnosed with Ph+ CML-CP within 3 months before enrollment;
  • \- The diagnosis documentation must include the type and quantitative level of the BCR-ABL1 transcript.
• Prior treatment with a maximum of 2 weeks of TKIs;
• Prior treatment with non-TKI regimens, including interferon and hydroxyurea, is allowed;
• Patients scheduled to initiate treatment with asciminib;
  • \- Patients beginning asciminib treatment must receive the first dose within 14 days of signing the ICF;
• Signed ICF.